{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T23:47:55Z","timestamp":1771026475388,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health Research","doi-asserted-by":"crossref","award":["15385"],"award-info":[{"award-number":["15385"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health Research","doi-asserted-by":"crossref","award":["178028"],"award-info":[{"award-number":["178028"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000001","name":"Alberta Cancer foundation","doi-asserted-by":"crossref","award":["26603"],"award-info":[{"award-number":["26603"]}],"id":[{"id":"10.13039\/501100000001","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13346-024-01782-9","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T15:27:29Z","timestamp":1738164449000},"page":"2833-2847","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Nano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics"],"prefix":"10.1007","volume":"15","author":[{"given":"Parnian","family":"Mehinrad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abdelfattah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sams M. A.","family":"Sadat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanin","family":"Shafaati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed H.","family":"Elmenoufy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-1425","authenticated-orcid":false,"given":"Michael","family":"Weinfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5108-7124","authenticated-orcid":false,"given":"Afsaneh","family":"Lavasanifar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"1782_CR1","doi-asserted-by":"publisher","first-page":"101174","DOI":"10.1016\/j.tranon.2021.101174","volume":"14","author":"Y Xi","year":"2021","unstructured":"Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14:101174. https:\/\/doi.org\/10.1016\/j.tranon.2021.101174.","journal-title":"Transl Oncol"},{"key":"1782_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021;325:669. https:\/\/doi.org\/10.1001\/jama.2021.0106.","journal-title":"JAMA"},{"key":"1782_CR3","doi-asserted-by":"publisher","first-page":"15065","DOI":"10.1038\/nrdp.2015.65","volume":"1","author":"EJ Kuipers","year":"2015","unstructured":"Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Primer. 2015;1:15065. https:\/\/doi.org\/10.1038\/nrdp.2015.65.","journal-title":"Nat Rev Dis Primer"},{"key":"1782_CR4","unstructured":"NCCN Clinical Prectice Guidelines in Oncology (NCCN Guidelines), Colon Cancer n.d."},{"key":"1782_CR5","doi-asserted-by":"publisher","first-page":"11261","DOI":"10.3390\/ijms231911261","volume":"23","author":"B Buyana","year":"2022","unstructured":"Buyana B, Naki T, Alven S, Aderibigbe BA. Nanoparticles loaded with platinum drugs for colorectal cancer therapy. Int J Mol Sci. 2022;23:11261. https:\/\/doi.org\/10.3390\/ijms231911261.","journal-title":"Int J Mol Sci"},{"key":"1782_CR6","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502\u201316. https:\/\/doi.org\/10.1038\/nrc1123.","journal-title":"Nat Rev Cancer"},{"key":"1782_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9\u201323. https:\/\/doi.org\/10.1016\/j.ctrv.2006.09.006.","journal-title":"Cancer Treat Rev"},{"key":"1782_CR8","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","volume":"14","author":"LP Martin","year":"2008","unstructured":"Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: The role of DNA repair pathways. Clin Cancer Res. 2008;14:1291\u20135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-2238.","journal-title":"Clin Cancer Res"},{"key":"1782_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s002800100363","volume":"48","author":"S Hector","year":"2001","unstructured":"Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol. 2001;48:398\u2013406. https:\/\/doi.org\/10.1007\/s002800100363.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"1782_CR10","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.3892\/mmr.2018.9507","volume":"18","author":"B Shen","year":"2018","unstructured":"Shen B, Mao W, Ahn J, Chung P, He P. Mechanism of HN-3 cell apoptosis induced by carboplatin: Combination of mitochondrial pathway associated with Ca2+ and the nucleus pathways. Mol Med Rep. 2018;18(6):4978\u201386. https:\/\/doi.org\/10.3892\/mmr.2018.9507.","journal-title":"Mol Med Rep"},{"key":"1782_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.pharmtox.48.080907.180426","volume":"48","author":"MD Hall","year":"2008","unstructured":"Hall MD, Okabe M, Shen D-W, Liang X-J, Gottesman MM. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 2008;48:495\u2013535. https:\/\/doi.org\/10.1146\/annurev.pharmtox.48.080907.180426.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1782_CR12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.2174\/092986709787458452","volume":"16","author":"M Knipp","year":"2009","unstructured":"Knipp M. Metallothioneins and Platinum(II) Anti-Tumor Compounds. Curr Med Chem. 2009;16:522\u201337. https:\/\/doi.org\/10.2174\/092986709787458452.","journal-title":"Curr Med Chem"},{"key":"1782_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.dnarep.2015.04.002","volume":"31","author":"EM McNeil","year":"2015","unstructured":"McNeil EM, Astell KR, Ritchie A-M, Shave S, Houston DR, Bakrania P, et al. Inhibition of the ERCC1\u2013XPF structure-specific endonuclease to overcome cancer chemoresistance. DNA Repair. 2015;31:19\u201328. https:\/\/doi.org\/10.1016\/j.dnarep.2015.04.002.","journal-title":"DNA Repair"},{"key":"1782_CR14","doi-asserted-by":"publisher","first-page":"7835","DOI":"10.1074\/jbc.273.14.7835","volume":"273","author":"WL de Laat","year":"1998","unstructured":"de Laat WL, Appeldoorn E, Jaspers NGJ, Hoeijmakers JHJ. DNA structural elements required for ERCC1-XPF endonuclease activity. J Biol Chem. 1998;273:7835\u201342. https:\/\/doi.org\/10.1074\/jbc.273.14.7835.","journal-title":"J Biol Chem"},{"key":"1782_CR15","doi-asserted-by":"publisher","unstructured":"Gaillard P-HL. Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair. Nucleic Acids Res 2001;29:872\u20139. https:\/\/doi.org\/10.1093\/nar\/29.4.872.","DOI":"10.1093\/nar\/29.4.872"},{"key":"1782_CR16","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.1093\/nar\/gkm503","volume":"35","author":"K Tripsianes","year":"2007","unstructured":"Tripsianes K, Folkers GE, Zheng C, Das D, Grinstead JS, Kaptein R, et al. Analysis of the XPA and ssDNA-binding surfaces on the central domain of human ERCC1 reveals evidence for subfunctionalization. Nucleic Acids Res. 2007;35:5789\u201398. https:\/\/doi.org\/10.1093\/nar\/gkm503.","journal-title":"Nucleic Acids Res"},{"key":"1782_CR17","doi-asserted-by":"publisher","first-page":"7684","DOI":"10.1021\/acs.jmedchem.9b00326","volume":"62","author":"AH Elmenoufy","year":"2019","unstructured":"Elmenoufy AH, Gentile F, Jay D, Karimi-Busheri F, Yang X, Soueidan OM, et al. Targeting DNA repair in tumor cells via inhibition of ERCC1\u2013XPF. J Med Chem. 2019;62:7684\u201396. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00326.","journal-title":"J Med Chem"},{"key":"1782_CR18","doi-asserted-by":"publisher","first-page":"28644","DOI":"10.1074\/jbc.M501083200","volume":"280","author":"Y-J Choi","year":"2005","unstructured":"Choi Y-J, Ryu K-S, Ko Y-M, Chae Y-K, Pelton JG, Wemmer DE, et al. Biophysical characterization of the interaction domains and mapping of the contact residues in the XPF-ERCC1 complex. J Biol Chem. 2005;280:28644\u201352. https:\/\/doi.org\/10.1074\/jbc.M501083200.","journal-title":"J Biol Chem"},{"key":"1782_CR19","doi-asserted-by":"publisher","first-page":"11236","DOI":"10.1073\/pnas.0504341102","volume":"102","author":"OV Tsodikov","year":"2005","unstructured":"Tsodikov OV, Enzlin JH, Sch\u00e4rer OD, Ellenberger T. Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF\u2013ERCC1. Proc Natl Acad Sci. 2005;102:11236\u201341. https:\/\/doi.org\/10.1073\/pnas.0504341102.","journal-title":"Proc Natl Acad Sci"},{"key":"1782_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1124\/mol.112.082347","volume":"84","author":"LP Jordheim","year":"2013","unstructured":"Jordheim LP, Barakat KH, Heinrich-Balard L, Matera E-L, Cros-Perrial E, Bouledrak K, et al. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. Mol Pharmacol. 2013;84:12\u201324. https:\/\/doi.org\/10.1124\/mol.112.082347.","journal-title":"Mol Pharmacol"},{"key":"1782_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/cbdd.13660","volume":"95","author":"F Gentile","year":"2020","unstructured":"Gentile F, Elmenoufy AH, Ciniero G, Jay D, Karimi-Busheri F, Barakat KH, et al. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein\u2013protein interaction. Chem Biol Drug Des. 2020;95:460\u201371. https:\/\/doi.org\/10.1111\/cbdd.13660.","journal-title":"Chem Biol Drug Des"},{"key":"1782_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00280-020-04213-x","volume":"87","author":"G Ciniero","year":"2021","unstructured":"Ciniero G, Elmenoufy AH, Gentile F, Weinfeld M, Deriu MA, West FG, et al. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1\u2013XPF-mediated DNA repair. Cancer Chemother Pharmacol. 2021;87:259\u201367. https:\/\/doi.org\/10.1007\/s00280-020-04213-x.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1782_CR23","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jconrel.2014.05.036","volume":"187","author":"CM Dawidczyk","year":"2014","unstructured":"Dawidczyk CM, Kim C, Park JH, Russell LM, Lee KH, Pomper MG, et al. State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines. J Controlled Release. 2014;187:133\u201344. https:\/\/doi.org\/10.1016\/j.jconrel.2014.05.036.","journal-title":"J Controlled Release"},{"key":"1782_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1517\/17425247.3.1.139","volume":"3","author":"HM Aliabadi","year":"2006","unstructured":"Aliabadi HM, Lavasanifar A. Polymeric micelles for drug delivery. Expert Opin Drug Deliv. 2006;3:139\u201362. https:\/\/doi.org\/10.1517\/17425247.3.1.139.","journal-title":"Expert Opin Drug Deliv"},{"key":"1782_CR25","doi-asserted-by":"publisher","first-page":"9419","DOI":"10.1021\/ma0613786","volume":"39","author":"A Mahmud","year":"2006","unstructured":"Mahmud A, Xiong X-B, Lavasanifar A. Novel self-associating Poly(ethylene oxide)- b lock -poly(\u03b5-caprolactone) block copolymers with functional side groups on the polyester block for drug delivery. Macromolecules. 2006;39:9419\u201328. https:\/\/doi.org\/10.1021\/ma0613786.","journal-title":"Macromolecules"},{"key":"1782_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.actbio.2015.06.017","volume":"24","author":"H Soleymani Abyaneh","year":"2015","unstructured":"Soleymani Abyaneh H, Vakili MR, Zhang F, Choi P, Lavasanifar A. Rational design of block copolymer micelles to control burst drug release at a nanoscale dimension. Acta Biomater. 2015;24:127\u201339. https:\/\/doi.org\/10.1016\/j.actbio.2015.06.017.","journal-title":"Acta Biomater"},{"key":"1782_CR27","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jconrel.2005.02.015","volume":"104","author":"HM Aliabadi","year":"2005","unstructured":"Aliabadi HM, Mahmud A, Sharifabadi AD, Lavasanifar A. Micelles of methoxy poly(ethylene oxide)-b-poly(\u025b-caprolactone) as vehicles for the solubilization and controlled delivery of cyclosporine A. J Controlled Release. 2005;104:301\u201311. https:\/\/doi.org\/10.1016\/j.jconrel.2005.02.015.","journal-title":"J Controlled Release"},{"key":"1782_CR28","doi-asserted-by":"publisher","first-page":"18867","DOI":"10.1021\/acsomega.9b02910","volume":"4","author":"A Saqr","year":"2019","unstructured":"Saqr A, Vakili MR, Huang Y-H, Lai R, Lavasanifar A. Development of traceable rituximab-modified PEO-Polyester micelles by postinsertion of PEG-phospholipids for targeting of b-cell lymphoma. ACS Omega. 2019;4:18867\u201379. https:\/\/doi.org\/10.1021\/acsomega.9b02910.","journal-title":"ACS Omega"},{"issue":"6","key":"1782_CR29","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1021\/acs.molpharmaceut.1c00918","volume":"19","author":"IM de Paiva","year":"2022","unstructured":"de Paiva IM, Vakili MR, Soleimani AH, Tabatabaei Dakhili SA, Munira S, Paladino M, et al. Biodistribution and activity of EGFR targeted polymeric micelles delivering a new inhibitor of DNA repair to orthotopic colorectal cancer xenografts with metastasis. Mol Pharm. 2022;19(6):1825\u201338. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00918.","journal-title":"Mol Pharm"},{"key":"1782_CR30","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/pharmaceutics12111033","volume":"12","author":"SMA Sadat","year":"2020","unstructured":"Sadat SMA, Vakili MR, Paiva IM, Weinfeld M, Lavasanifar A. Development of self-associating SN-38-Conjugated Poly(ethylene oxide)-Poly(ester) micelles for colorectal cancer therapy. Pharmaceutics. 2020;12:1033. https:\/\/doi.org\/10.3390\/pharmaceutics12111033.","journal-title":"Pharmaceutics"},{"key":"1782_CR31","doi-asserted-by":"publisher","first-page":"819172","DOI":"10.3389\/fonc.2022.819172","volume":"12","author":"C Weilbeer","year":"2022","unstructured":"Weilbeer C, Jay D, Donnelly JC, Gentile F, Karimi-Busheri F, Yang X, et al. Modulation of ERCC1-XPF heterodimerization inhibition via structural modification of small molecule inhibitor side-chains. Front Oncol. 2022;12:819172. https:\/\/doi.org\/10.3389\/fonc.2022.819172.","journal-title":"Front Oncol"},{"key":"1782_CR32","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.3390\/pharmaceutics14122795","volume":"14","author":"N Jackson","year":"2022","unstructured":"Jackson N, Alhussan A, Bromma K, Jay D, Donnelly JC, West FG, et al. Repurposing antimalarial pyronaridine as a DNA repair inhibitor to exploit the full potential of gold-nanoparticle-mediated radiation response. Pharmaceutics. 2022;14:2795. https:\/\/doi.org\/10.3390\/pharmaceutics14122795.","journal-title":"Pharmaceutics"},{"key":"1782_CR33","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.biomaterials.2009.09.080","volume":"31","author":"X-B Xiong","year":"2010","unstructured":"Xiong X-B, Ma Z, Lai R, Lavasanifar A. The therapeutic response to multifunctional polymeric nano-conjugates in the targeted cellular and subcellular delivery of doxorubicin. Biomaterials. 2010;31:757\u201368. https:\/\/doi.org\/10.1016\/j.biomaterials.2009.09.080.","journal-title":"Biomaterials"},{"key":"1782_CR34","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NAP Franken","year":"2006","unstructured":"Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315\u20139. https:\/\/doi.org\/10.1038\/nprot.2006.339.","journal-title":"Nat Protoc"},{"key":"1782_CR35","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/cancers3011351","volume":"3","author":"A-M Florea","year":"2011","unstructured":"Florea A-M, B\u00fcsselberg D. Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers. 2011;3:1351\u201371. https:\/\/doi.org\/10.3390\/cancers3011351.","journal-title":"Cancers"},{"key":"1782_CR36","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/emboj.2009.49","volume":"28","author":"L Staresincic","year":"2009","unstructured":"Staresincic L, Fagbemi AF, Enzlin JH, Gourdin AM, Wijgers N, Dunand-Sauthier I, et al. Coordination of dual incision and repair synthesis in human nucleotide excision repair. EMBO J. 2009;28:1111\u201320. https:\/\/doi.org\/10.1038\/emboj.2009.49.","journal-title":"EMBO J"},{"key":"1782_CR37","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.molcel.2014.03.015","volume":"54","author":"D Klein Douwel","year":"2014","unstructured":"Klein Douwel D, Boonen RACM, Long DT, Szypowska AA, R\u00e4schle M, Walter JC, et al. XPF-ERCC1 acts in unhooking DNA interstrand crosslinks in cooperation with FANCD2 and FANCP\/SLX4. Mol Cell. 2014;54:460\u201371. https:\/\/doi.org\/10.1016\/j.molcel.2014.03.015.","journal-title":"Mol Cell"},{"key":"1782_CR38","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1128\/MCB.21.3.713-720.2001","volume":"21","author":"X Wang","year":"2001","unstructured":"Wang X, Peterson CA, Zheng H, Nairn RS, Legerski RJ, Li L. Involvement of nucleotide excision repair in a recombination-independent and error-prone pathway of DNA interstrand cross-link repair. Mol Cell Biol. 2001;21:713\u201320. https:\/\/doi.org\/10.1128\/MCB.21.3.713-720.2001.","journal-title":"Mol Cell Biol"},{"key":"1782_CR39","doi-asserted-by":"publisher","first-page":"6928","DOI":"10.3390\/ijms21186928","volume":"21","author":"S Schoch","year":"2020","unstructured":"Schoch S, Gajewski S, Rothfu\u00df J, Hartwig A, K\u00f6berle B. Comparative study of the mode of action of clinically approved platinum-based chemotherapeutics. Int J Mol Sci. 2020;21:6928. https:\/\/doi.org\/10.3390\/ijms21186928.","journal-title":"Int J Mol Sci"},{"key":"1782_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.critrevonc.2004.08.008","volume":"53","author":"SG Chaney","year":"2005","unstructured":"Chaney SG, Campbell SL, Bassett E, Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol. 2005;53:3\u201311. https:\/\/doi.org\/10.1016\/j.critrevonc.2004.08.008.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1782_CR41","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nm.4291","volume":"23","author":"PM Bruno","year":"2017","unstructured":"Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, et al. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med. 2017;23:461\u201371. https:\/\/doi.org\/10.1038\/nm.4291.","journal-title":"Nat Med"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01782-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-024-01782-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-024-01782-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T16:44:06Z","timestamp":1751388246000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-024-01782-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1782"],"URL":"https:\/\/doi.org\/10.1007\/s13346-024-01782-9","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"20 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies performed on human cell lines have received biosafety and ethics approval from University of Alberta (Pro000891).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable. Human subjects were not part of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following competing financial interest(s): DNA repair inhibitor in this manuscript (A4) has been included in a US patent application file (PCT\/CA2020\/050823). Afsaneh Lavasanifar is co-Founder and Chief scientific officer of Meros Polymers which has the license to PEO-b-PBCL polymer used in this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}